Mutations in the STK11 gene are observed in approximately 8% to 39% of patients with NSCLC; this gene negatively regulates the mTOR signaling pathway, which is involved in several essential cellular processes such as nutritional signals, the regulation of protein synthesis, cell growth, and metabolic modulation [53,54]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.